Orchid Can't Nix Roche Boniva Patent - News, Articles, and Events

Jennifer Manton
Chief Marketing Officer
212.407.4112

Orchid Can't Nix Roche Boniva Patent

March 18, 2011 | Law360

Loeb & Loeb LLP's Mark Waddell, Paula Colbath and Joshua Harris are noted as counsel for Hoffmann-La Roche Inc. in the pharmaceutical company's infringement actions against Orchid Chemicals & Pharmaceuticals Ltd. over Orchid's proposed generic version of the branded osteoporosis drug Boniva^®. A federal judge rejected Orchid's bid to toss one of the five Boniva^® patents asserted by Roche to prevent Orchid from marketing the generic drug.

Mark E. Waddell
Paula K. Colbath
Joshua H. Harris

Patent Litigation and Counseling

This Web site may constitute "Attorney Advertising" under the New York Rules of Professional Conduct and under the law of other jurisdictions.
Your use of our Web site or its facilities constitutes your acceptance of the Terms of Use and Privacy Policy, which are accessible in the link at the bottom left of this page.